C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter B—Food for Human ConsumptionPart 130—Food Standards: GeneralSubpart A—General Provisions

21 C.F.R. § 130.9 (2026)

Sulfites in standardized food

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1967–2009 8citing cases
At a glance

Courts have cited this section in 8 opinions since 1967.

(a) Any standardized food that contains a sulfiting agent or combination of sulfiting agents that is functional and provided for in the applicable standard or that is present in the finished food at a detectable concentration is misbranded unless the presence of the sulfiting agent or agents is declared on the label of the food. A detectable amount of sulfiting agent is 10 parts per million (ppm or mg/kg) or more of the sulfite in the finished food. The concentration of sulfite in the finished food will be determined using either:

(1) Determination of Sulfite in Food by Liquid Chromatography Tandem Mass Spectrometry; or

(2) AOAC Official Method 990.28.

(b) Any standardized food that, as a result of actions that are consistent with current good manufacturing practice, contains an indirectly added sulfiting agent that has no functional effect in the food and that would, in the absence of § 101.100(a)(4) of this chapter, be considered to be an incidental additive for purposes of § 130.8, conforms to the applicable definition and standard of identity if the presence of the sulfiting agent is declared on the label of the food.

(c) The standards required in this section are incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. All approved material is available for inspection at the Food and Drug Administration, Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, and available from AOAC International, 2275 Research Blvd., Ste. 300, Rockville, MD 20850-3250. It is also available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, email [email protected] or go to www.archives.gov/federal-register/cfr/ibr-locations.html.

(1) AOAC Official Method 990.28, Sulfites in Foods, Optimized Monier-Williams Method, Section 47.3.43, Official Methods of Analysis, 21st edition, 2019.

(2) Determination of Sulfite in Food by Liquid Chromatography Tandem Mass Spectrometry: Collaborative Study, Katherine S. Carlos and Lowri S. De Jager; Journal of AOAC International, Vol. 100, No. 6, 2017, pp. 1785-1794.

[58 FR 2876, Jan. 6, 1993, as amended at 63 FR 14035, Mar. 24, 1998; 87 FR 2547, Jan. 18, 2022]
The 8 cases that cite 21 C.F.R. § 130.9 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBartlett v. Mut. Pharm. Co., 659 F. Supp. 2d 279 (D.N.H. 2009).
cites § 130.9 2×cited by 21 cases
Where it cites § 130.9
“30, 1965) (later codified at 21 C.F.R. § 130.9 (d)(1) (1965)). To effect this goal, the FDA announced in the rule a policy “to take no action against a drug or applicant solely because changes of [this] kind .”
The case’s holding
Federal drug-labeling law does not impliedly preempt state-law failure-to-warn claims against a generic drug manufacturer, because federal rules allow post-approval labeling changes that could have strengthened the warnings.
Later courts cite it for
“the fda's remarks in proposing and promulgating these regulations” · 2 citing courts
2
GREENSidney Roginsky v. Richardson-Merrell, Inc., 378 F.2d 832 (2d Cir. 1967).
cites § 130.9 2×cited by 235 cases
Where it cites § 130.9
“12595 (1960), 21 C.F.R. § 130.9 (1963 ed.). Believing defendant’s proposed letter to be too weak, the FDA withheld permission and insisted on a much stronger one which was approved on November 27 and mailed on December 1 to every doctor in the country and also to defendant’s…”
The case’s holding
Punitive damages against a corporation require proof that management authorized, participated in, or ratified conduct amounting to recklessness close to criminality rather than mere negligence.
Later courts cite it for
“the gravest difficulty in perceiving how claims for punitive damages in such a multiplicity of actions throughout the nation can be so administered as to avoid overkill.” · 7 citing courts
3
GREENMcEwen v. Ortho Pharm. Corp., 528 P.2d 522 (Or. 1974).
cites § 130.9 2×cited by 178 cases
Where it cites § 130.9
“"* * * * * “ (e) It will be the policy of the Food and Drug Administration to take no action against a drug or applicant solely because changes of the kinds described in paragraph (d) of this section are placed in effect by the applicant prior to his receipt of a written notice…”
The case’s holding
A drug manufacturer is directly liable to a patient for breaching its duty to warn the medical profession of dangerous side effects.
Later courts cite it for
“although the duty of the ethical drug manufacturer is to warn the doctor, rather than the patient, the manufacturer is directly liable to the patient for a breach of such duty.” · 8 citing courts
4
REDFeldman v. Lederle Labs., 561 A.2d 288 (N.J. Super. Ct. App. Div. 1989).
cites § 130.9 3×cited by 11 cases
Reversed by Feldman v. Lederle Laboratories (1991): the Supreme Court of New Jersey's own opinion in this case.
The case’s holding
Federal law preempts state failure-to-warn claims when a manufacturer cannot change product labeling without FDA approval and the agency has rejected the proposed warning.
Later courts cite it for
“congress' overriding purpose in enacting the fdca was to protect consumers from dangerous drugs and antibiotics,” · 1 citing court
5
GREENWitczak v. Pfizer, Inc., 377 F. Supp. 2d 726 (D. Minn. 2005).
cites § 130.9 1×cited by 17 cases
Where it cites § 130.9
“The regulation was originally codified at 21 C.F.R. § 130.9 (d); it then became 21 C.”
Later courts cite it for
“congress certainly did not intend to bar drug companies from protecting the public when enacting the fdca; its goal was to protect the public. . . . any contrary interpretation of congress's intent is perverse.” · 2 citing courts
6
NO FLAGCambiano v. Am. Cyanamid Co., 747 F. Supp. 543 (E.D. Mo. 1989).
cites § 130.9 1×cited by 1 case
Where it cites § 130.9
“In 1965, about two years after the warning label was required, the FDA regulations were amended to insert 21 C.F.R. §§ 130.9 (d) and (e) which provide: (d) Changes of the following kinds proposed in supplemental new drug applications should be placed into effect at the earliest…”
7
GREENBartlett v. Mut. Pharm., 2009 DNH 144 (D.N.H. 2009).
cites § 130.9 2×cited by 0 cases
Where it cites § 130.9
“3 0 , 1965) (later codified at 21 C.F.R. § 130.9 (d)(1) (1965)). To effect this goal, the FDA announced in the rule a policy “to take no action against a drug or applicant solely because changes of [this] kind .”
8
GREENIn re Tetracycline Cases, 747 F. Supp. 543 (W.D. Mo. 1989).
cites § 130.9 1×cited by 0 cases
Where it cites § 130.9
“In 1965, about two years after the warning label was required, the FDA regulations were amended to insert 21 C.F.R. §§ 130.9 (d) and (e) which provide: (d) Changes of the following kinds proposed in supplemental new drug applications should be placed into effect at the earliest…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
196719882009

One bar per year. Tallest: 3 cases in 1989. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.N.H.22d Cir.1D. Minn.1E.D. Mo.1W.D. Mo.1N.J. Super. Ct. App. Div.1Or.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com